The glucagon-like peptide 1 (GLP-1) agonist market is almost 20 years old, with 10 different products available for the treatment of type 2 diabetes (T2D) and weight loss. With their ability to control blood sugar levels, GLP-1s have also demonstrated positive impacts on weight loss and reduced cardiovascular risks. This blog digs deeper, examining the demand behind this growth and the resulting impact on GLP-1s beyond Mounjaro. The clinical efficacy of GLP-1s, combined with consumer demand and influence, is notable among not only the diabetes and weight loss medications, but for the industry overall. While transitional assistance has stepped in for some, nearly 60% of written GLP-1 prescriptions remained unfilled in the first half of 2023.

Source: New York Times September 05, 2023 05:07 UTC